Abstract: A method of detecting one or more change in an eye and a method diagnosing or providing an indication of an eye disease or eye condition or a neurodegenerative disease or condition, or a predisposition thereto are disclosed. The method of detection comprises comparing an image of the eye with at least one asynchronous image of the eye to thereby detect the one or more change in the eye wherein the change comprises a darkening or lightening in pigment of the Retinal Pigmented Epithelium (RPE) in the macula. The method of diagnosing or providing an indication of an eye disease or eye condition or a neurodegenerative disease or condition or a predisposition thereto comprises the same comparison and when the change is detected, providing a diagnosis of, indication of or to an eye disease or eye condition or a neurodegenerative disease or condition or a predisposition thereto.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: An automated burrito maker is described, including a filling station for providing a quantity of burrito filling on an upper surface of tortillas on a first belt, an air supply positioned below a gap between the first belt and a second belt for delivering an air blast to lift a leading edge of each tortilla moving over the gap, a front fold station for crimping the leading edge of the tortilla toward the upper tortilla surface and around at least a portion of the burrito filling, a first side fold station having a first folding rail for wrapping the first tortilla side over at least a portion of the burrito filling, and a second side fold station having a second folding rail for wrapping the second tortilla side over at least a portion of the burrito filling and at least a portion of the first side of the tortilla.

Abstract: A unit dose pharmaceutical composition comprising 2.0 to 8.0 mg of a dry powder of one or more glucocorticoid or mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof; wherein the composition is comprised in a syringe is disclosed. The composition may also comprise a a sterile, liquid carrier suitable for direct injection into an eye and/or 0.6 to 0.75% (w/v) of carboxy methyl cellulose (CMC); and 0.015 to 0.04 (w/v) of a surfactant. Also disclosed is a medical device comprising the unit dose pharmaceutical composition, use of the pharmaceutical composition in the treatment of an eye disease or condition or predisposition thereto and a method of treatment of an eye disease or condition or a predisposition thereto in a subject in need thereof including injecting into the eye the pharmaceutical formulation. The injection may comprise an intravitreal and/or suprachoroidal injection.

Abstract: An inspection system is provided for a pre-filled blow-fill-seal (BFS) product. The BFS product comprises a neck that extends along a longitudinal direction and has a coupling portion that protrudes laterally outward with respect to adjacent portions of the neck. The inspection system comprises a controller and a first inspection station, which includes illumination and detection assemblies. Interrogating light from one or more light sources of the illumination assembly is directed at a perimeter of the coupling portion of the neck. The detection assembly has an input optical axis that extends along the longitudinal direction and comprises an imaging device to detect light emitted from the neck. The controller is configured to determine compliance of the BFS product with respect to predetermined criteria based at least in part on the light detected by the imaging device.

Abstract: A unit dose pharmaceutical composition comprising 2.0 to 8.0 mg of a dry powder of one or more glucocorticoid or mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof; wherein the composition is comprised in a syringe is disclosed. The composition may also comprise a a sterile, liquid carrier suitable for direct injection into an eye and/or 0.6 to 0.75% (w/v) of carboxy methyl cellulose (CMC); and 0.015 to 0.04 (w/v) of a surfactant. Also disclosed is a medical device comprising the unit dose pharmaceutical composition, use of the pharmaceutical composition in the treatment of an eye disease or condition or predisposition thereto and a method of treatment of an eye disease or condition or a predisposition thereto in a subject in need thereof including injecting into the eye the pharmaceutical formulation. The injection may comprise an intravitreal and/or suprachoroidal injection.

Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: The present invention relates to methods of treating or preventing AMD in a subject, the method comprising administering to the subject a therapeutically effective amount of hemp, hemp oil or pharmaceutically effective extract thereof to thereby treat or prevent the AMD. The invention also relates to pharmaceutical composition comprising a therapeutically effective amount of hemp, hemp oil; or a pharmaceutically effective extract thereof and a pharmaceutically acceptable carrier, diluent or excipient when used to treat AMD, and to uses of a pharmaceutical composition comprising hemp, hemp oil, or a pharmaceutically effective extract thereof for the manufacture of a medicament for the treatment of AMD.

Abstract: A method of treating dry AMD in a subject includes administering to the subject a therapeutically effective amount of an anti-inflammatory to thereby treat the dry AMD. Also disclosed is a pharmaceutical composition including a therapeutically effective amount of one or more anti-inflammatory and a pharmaceutically acceptable carrier, diluent or excipient when used to treat dry AMD and use of the pharmaceutical composition for the manufacture of a medicament for the treatment of dry AMD. The one or more anti-inflammatory may comprise one or more of a COX inhibitor, one or more mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof, one or more glucocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof, an antileukotrine and/or a leukotriene receptor antagonist. In one embodiment the anti-inflammatory includes fludrocortisone.

Abstract: A subject of the present invention is the use of a compound having the general formula (I): (I) wherein V, W, X4, X5, X6, X7, X?4, X?5, X?6, X?7, Y, Y?, R3, R?3, R4 and R?4 are as defined in any one of claims 1 to 11, for the detection, capture and/or separation of polluting gases, in particular those selected from the group comprising carbon dioxide, methane, sulfur dioxide, nitrogen oxides, carbon monoxide, linear hydrocarbons, linear mono-olefins and their mixtures, and preferably carbon dioxide. Another subject of the invention is a compound of formula (I) wherein V, W, X4, X5, X6, X7, X?4, X?5, X?6, X?7, Y, Y?, R3, R?3, R4 and R?4 are as defined in any one of claims 12 to 21.

Abstract: A packaged food product processing machine. The machine comprises a food consumer interface configured to receive a food consumer selection identifying an end state of a food product, a package cooling sub-system comprising a chilled fluid bath, a gripper component configured to agitate a package containing the food product in the chilled fluid bath, and a controller configured to command the gripper to control the rate of heat transfer from the package to the chilled fluid bath based on receiving an input identifying an end state selection from the food consumer interface and based on receiving an input containing a value of the physical parameter of the food product from the gripper component.

Abstract: A unit dose pharmaceutical composition comprising 2.0 to 8.0 mg of a dry powder of one or more glucocorticoid or mineralocorticoid or a therapeutically active analogue, derivative, homolog, pharmaceutically acceptable salt or conjugate thereof; wherein the composition is comprised in a syringe is disclosed. The composition may also comprise a a sterile, liquid carrier suitable for direct injection into an eye and/or 0.6 to 0.75% (w/v) of carboxy methyl cellulose (CMC); and 0.015 to 0.04 (w/v) of a surfactant. Also disclosed is a medical device comprising the unit dose pharmaceutical composition, use of the pharmaceutical composition in the treatment of an eye disease or condition or predisposition thereto and a method of treatment of an eye disease or condition or a predisposition thereto in a subject in need thereof including injecting into the eye the pharmaceutical formulation. The injection may comprise an intravitreal and/or suprachoroidal injection.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Abstract: A financial transaction system includes a governing host having a database for registering parties wishing to perform a financial transaction and processing the financial transaction. A discrete point-of-sale (POS) terminal interfaces with one party wishing to initiate a financial transaction with another party. The discrete POS terminal has a local transaction process providing for initial validating and enforcing of business rules governing the transaction with the one party and generating a transaction key confirming that the transaction is authorised on validating the transaction with the governing host. A facilitator device reads the transaction key on being supplied with same by the one party and communicates with the governing host to complete the transaction using the facilitator POS terminal.